Jump to content
RemedySpot.com

Efficacy of human growth hormone in children with JRA & Growth Failure

Rate this topic


Guest guest

Recommended Posts

1: J Pediatr Endocrinol Metab 2000 Jul-Aug;13(7):899-905

Efficacy of recombinant human growth hormone in children with juvenile rheumatoid arthritis and growth failure.Al-Mutair A, Bahabri S, Al-Mayouf S, Al-Ashwal A.Department of Pediatrics, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.Ten patients with juvenile rheumatoid arthritis (JRA) and growth failure were treated with recombinant human growth hormone (GH) for 1 to 3 years at a dosage of 0.57 IU/kg/wk. All the patients had been on prednisone at a mean dosage of 4.12 mg p.o. daily. GH was low in one patient, two patients had a borderline level and seven patients had adequate response to provocative tests or post-sleep measurement. Serum IGF-I was found to be low in five of six patients.

Mean growth velocity increased from 2.45 cm/yr to 4.79 cm/yr after 1 year's treatment with GH. Six patients continued on GH treatment for a second year and continued to have a better growth velocity, with a mean of 5.43 cm/yr. Two patients entered puberty during the second year of GH treatment. This study demonstrates the potential beneficial effect of GH treatment in patients with JRA with growth failure of systemic onset or polyarticular onset who are on prednisone. Further study is needed to determine the long-term effect of GH treatment on ultimate height.PMID: 10968478 [PubMed - indexed for MEDLINE]

Link to comment
Share on other sites

  • 1 month later...

----------

From: " Georgina " <gmckin@...>

Reply-

Date: Fri, 28 Dec 2001 14:07:37 -1000

" a JRA List " < >

Subject: Efficacy of human growth hormone in children with JRA & Growth Failure

1: J Pediatr Endocrinol Metab 2000 Jul-Aug;13(7):899-905

Efficacy of recombinant human growth hormone in children with juvenile rheumatoid arthritis and growth failure.

Al-Mutair A, Bahabri S, Al-Mayouf S, Al-Ashwal A.

Department of Pediatrics, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

Ten patients with juvenile rheumatoid arthritis (JRA) and growth failure were treated with recombinant human growth hormone (GH) for 1 to 3 years at a dosage of 0.57 IU/kg/wk. All the patients had been on prednisone at a mean dosage of 4.12 mg p.o. daily. GH was low in one patient, two patients had a borderline level and seven patients had adequate response to provocative tests or post-sleep measurement. Serum IGF-I was found to be low in five of six patients.

Mean growth velocity increased from 2.45 cm/yr to 4.79 cm/yr after 1 year's treatment with GH. Six patients continued on GH treatment for a second year and continued to have a better growth velocity, with a mean of 5.43 cm/yr. Two patients entered puberty during the second year of GH treatment. This study demonstrates the potential beneficial effect of GH treatment in patients with JRA with growth failure of systemic onset or polyarticular onset who are on prednisone. Further study is needed to determine the long-term effect of GH treatment on ultimate height.

PMID: 10968478 [PubMed - indexed for MEDLINE]

Link to comment
Share on other sites

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...